| Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need MC Field, D Horn, AH Fairlamb, MAJ Ferguson, DW Gray, KD Read, ... Nature Reviews Microbiology 15 (4), 217-231, 2017 | 421 | 2017 |
| Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani S Wyllie, ML Cunningham, AH Fairlamb Journal of Biological Chemistry 279 (38), 39925-39932, 2004 | 416 | 2004 |
| Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects S Patterson, S Wyllie Trends in parasitology 30 (6), 289-298, 2014 | 367 | 2014 |
| Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay M De Rycker, I Hallyburton, J Thomas, L Campbell, S Wyllie, D Joshi, ... Antimicrobial agents and chemotherapy 57 (7), 2913-2922, 2013 | 168 | 2013 |
| The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis S Wyllie, S Patterson, L Stojanovski, FRC Simeons, S Norval, R Kime, ... Science translational medicine 4 (119), 119re1-119re1, 2012 | 167 | 2012 |
| Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis AY Sokolova, S Wyllie, S Patterson, SL Oza, KD Read, AH Fairlamb Antimicrobial agents and chemotherapy 54 (7), 2893-2900, 2010 | 145 | 2010 |
| Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition S Wyllie, S Brand, M Thomas, M De Rycker, C Chung, I Pena, ... Proceedings of the National Academy of Sciences 116 (19), 9318-9323, 2019 | 139 | 2019 |
| Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis S Wyllie, M Thomas, S Patterson, S Crouch, M De Rycker, R Lowe, ... Nature 560 (7717), 192-197, 2018 | 130 | 2018 |
| Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony G Mandal, S Wyllie, N Singh, S Sundar, AH Fairlamb, M Chatterjee Parasitology 134 (12), 1679-1687, 2007 | 121 | 2007 |
| Clinical and veterinary trypanocidal benzoxaboroles target CPSF3 RJ Wall, E Rico, I Lukac, F Zuccotto, S Elg, IH Gilbert, Y Freund, ... Proceedings of the National Academy of Sciences 115 (38), 9616-9621, 2018 | 118 | 2018 |
| Trypanothione biosynthesis in Leishmania major SL Oza, MP Shaw, S Wyllie, AH Fairlamb Molecular and biochemical parasitology 139 (1), 107-116, 2005 | 114 | 2005 |
| The Major Outer Membrane Protein of Chlamydia psittaci Functions as a Porin-Like Ion Channel S Wyllie, RH Ashley, D Longbottom, AJ Herring Infection and immunity 66 (11), 5202-5207, 1998 | 113 | 1998 |
| Roles of Trypanothione S-Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials S Wyllie, TJ Vickers, AH Fairlamb Antimicrobial Agents and Chemotherapy 52 (4), 1359-1365, 2008 | 104 | 2008 |
| Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line S Wyllie, AH Fairlamb Biochemical pharmacology 71 (3), 257-267, 2006 | 102 | 2006 |
| Chemical validation of trypanothione synthetase LS Torrie, S Wyllie, D Spinks, SL Oza, S Thompson, JR Harrison, ... Journal of Biological Chemistry 284 (52), 36137-36145, 2009 | 95 | 2009 |
| Dissecting the essentiality of the bifunctional trypanothione synthetase‐amidase in Trypanosoma brucei using chemical and genetic methods S Wyllie, SL Oza, S Patterson, D Spinks, S Thompson, AH Fairlamb Molecular microbiology 74 (3), 529-540, 2009 | 94 | 2009 |
| Anti-trypanosomatid drug discovery: progress and challenges M De Rycker, S Wyllie, D Horn, KD Read, IH Gilbert Nature Reviews Microbiology 21 (1), 35-50, 2023 | 89 | 2023 |
| Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania S Wyllie, AJ Roberts, S Norval, S Patterson, BJ Foth, M Berriman, ... PLoS pathogens 12 (11), e1005971, 2016 | 88 | 2016 |
| Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei S Wyllie, BJ Foth, A Kelner, AY Sokolova, M Berriman, AH Fairlamb Journal of Antimicrobial Chemotherapy 71 (3), 625-634, 2016 | 87 | 2016 |
| The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis S Patterson, S Wyllie, S Norval, L Stojanovski, FRC Simeons, JL Auer, ... Elife 5, e09744, 2016 | 85 | 2016 |
